AFM
CLRB icon

Anson Funds Management’s Cellectar Biosciences CLRB Stock Holding History

Anson Funds Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-127
Closed -$523K – 32
2017
Q4 		$523K Buy
+127
New +$567K 0.35% 31

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
IGGA
Iron Gate Global Advisors Nsl, Utah $947M AUM 23.59% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIM
Sonora Investment Management Tucson, Arizona $798M AUM 17.61% 1-Year Est. Return

Anson Funds Management's CLRB Position: Q1 2018 in Review

Anson Funds Management sold out of Cellectar Biosciences (CLRB) in Q1 2018, closing a stake of 127 shares — an estimated $523K sold.

Anson Funds Management first reported a position in CLRB in Q4 2017 and held it in 1 quarter. The position peaked at $523K in Q4 2017. 10 funds tracked by Wall St. Rank hold CLRB as of Q1 2018.

  • Anson Funds Management reported no remaining Cellectar Biosciences position as of Q1 2018 after selling out during the quarter.
  • Anson Funds Management sold 127 Cellectar Biosciences shares in Q1 2018, an estimated $523K.
  • Anson Funds Management first reported a position in Cellectar Biosciences in Q4 2017 and held it in 1 quarter.
  • Anson Funds Management's Cellectar Biosciences position peaked at $523K in Q4 2017.
  • 10 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2018.

Based on Anson Funds Management's 13F filing for Q1 2018, filed 15 May 2018.